NCT01707329View on ClinicalTrials.gov

Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment

PHASE2UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Chemotherapy

Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.

DRUG

Icotinib+chemotherapy

Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.

Trial Locations (6)

310000

ACTIVE_NOT_RECRUITING

Sir Run Run Shaw Hospital, Hangzhou

ACTIVE_NOT_RECRUITING

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

ACTIVE_NOT_RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

325000

ACTIVE_NOT_RECRUITING

The First Affiliated Hospital of Wenzhou Medical College, Wenzhou

410205

ACTIVE_NOT_RECRUITING

Hunan Province Tumor Hospital, Changsha

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT01707329 - Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment | Biotech Hunter | Biotech Hunter